Clin2
NCT07591727Possibly a fitNot yet recruiting

Gut-X-001 Oral Medication for Alzheimer's Disease

Alzheimer s Disease

Part of Brain & nervous system clinical trials.

This study tests an experimental oral medication called Gut-X-001 that may help slow thinking and memory problems in people with Alzheimer's disease by working through the gut. You'll take the medication for several months while doctors monitor your cognitive health and safety.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
120 people
Ages
50 years to 85 years
Study type
Interventional

Who can take part

  • Age between 50 and 85 years old
  • Confirmed Alzheimer's disease diagnosis with at least one abnormal biomarker (blood or spinal fluid test showing amyloid or tau protein problems)
  • Memory and thinking scores in a specific range based on your education level
  • A reliable caregiver who can spend at least 4 days per week and 2+ hours per day with you and attend all visits
  • Stable doses of any Alzheimer's medications for at least 3 months before starting the study
  • No other serious brain, heart, or liver conditions that could interfere with the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05413655Recruiting· Phase 2
Oral drug for mild Alzheimer’s disease symptoms

This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.

Taipei
NCT07058688Recruiting· Phase 2
Testing a new drug for Alzheimer's (NTRX-07)

This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.

Brno
NCT05183321Not yet recruiting
Drug treatment for gum disease in people with Alzheimer’s

This trial studies whether treating periodontal (gum) disease can help people who have probable Alzheimer’s disease. You may take a study treatment and have regular checks by a caregiver and study team.

NCT05908695Recruiting· Phase 4
GV-971 treatment for mild to moderate Alzheimer’s disease

This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.

Huainan, Anhui
NCT07252440Recruiting· Phase 2
Testing an oral drug for early Alzheimer's disease

This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.

Chongqing, Chongqing Municipality
NCT07011732Recruiting· Phase 3
Testing a drug for Alzheimer's-related agitation

This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.

Scottsdale, Arizona

Hear when a new Alzheimer s Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.